Milbemax tablets for Small Cats and Kittens

Main information

  • Trade name:
  • Milbemax tablets for Small Cats and Kittens
  • Pharmaceutical form:
  • Tablet
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • Milbemax tablets for Small Cats and Kittens
    Greece
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • Milbemycin, combinations
  • Therapeutic area:
  • Cats

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • FR/V/0135/003
  • Authorization date:
  • 17-04-2011
  • EU code:
  • FR/V/0135/003
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

MILBEMAXkittenFinalRENEWALSPCJuly2007

SummaryofProductCharacteristics

1. NAMEOFTHEVETERINARYMEDICINALPRODUCT

MILBEMAX ®

Film-coatedtabletsforsmallcatsandkittens

2. QUALITATIVEANDQUANTITATIVECOMPOSITION

Eachtabletcontains:

Activesubstances:

Milbemycinoxime

Praziquantel

4mg

10mg

Excipients:

Titaniumdioxide(E171)

Ironoxide(E172) 0.608mg

0.016mg

ExcipientsQSPonedivisabletabletof130mg

Forafulllistofexcipients,seesection6.1

3. PHARMACEUTICALFORM

Film-coatedtablet

Oblongshaped,pink,withascoreononeside.Onesidebearstheimprint“BC”,the

otherside“NA”.

4. CLINICALPARTICULARS

4.1 Targetspecies

Cats

4.2 Indicationsforuse

MILBEMAXkittenFinalRENEWALSPCJuly2007

Incats:treatmentofmixedinfectionsbyimmatureandadultcestodesand

nematodesofthefollowingspecies:

-Cestodes:

Dipylidiumcaninum

Taeniaspp.

Echinococcusmultilocularis

-Nematodes:

Ancylostomatubaeforme

Toxocaracati

Preventionofheartwormdisease(Dirofilariaimmitis)ifconcomitanttreatmentagainst

cestodesisindicated.

4.3 Contra-indications

Donotuseincatsoflessthan6weeksofageand/orweighinglessthan0.5kg

4.4 Specialwarnings

None

4.5 Specialprecautionsforuse,includingspecialprecautionstobetakenby

thepersonadministeringthemedicinalproducttoanimals

Specialprecautionsforuseinanimals

Aspergoodveterinarypractice,animalsshouldbeweighedtoensureaccurate

dosing

Echinococcosisrepresentsahazardforhumans.IncaseofEchinococcosis,specific

guidelinesonthetreatmentandfollowupandonthesafeguardofpersonshavetobe

followed.Expertsorinstitutesofparasitologyshouldbeconsulted.

Nostudieshavebeenperformedwithseverelydebilitatedcatsorindividualswith

seriouslycompromisedkidneyorliverfunction.Theproductisnotrecommendedfor

suchanimalsoronlyaccordingtoabenefit/riskassessmentbytheresponsible

veterinarian.

Specialprecautionstobetakenbythepersonadministeringtheveterinary

producttoanimals

Washhandsafteruse.

Intheeventofaccidentalingestionofthetablets,particularlybyachild,seekmedical

adviceimmediatelyandshowthepackageleafletorthelabeltothedoctor.

MILBEMAXkittenFinalRENEWALSPCJuly2007

4.6 Adversereactions(frequencyandseriousness)

"Inveryrareoccasions,especiallyinyoungcats,systemicsigns(suchaslethargy),

neurologicalsigns(suchasataxiaandmuscletremors)and/orgastrointestinalsigns

(suchasemesisanddiarrhoea.)havebeenobservedafteradministrationofthe

veterinarymedicinalproduct."

4.7 Useduringpregnancyandlactation

MILBEMAXcanbeusedinbreedingcatsincludingpregnantandlactatingqueens.

4.8 Interactionwithothermedicamentsandotherformsofinteraction

TheconcurrentuseofMILBEMAXwithselamectiniswelltolerated.Nointeractions

wereobservedwhentherecommendeddoseofthemacrocycliclactoneselamectin

wasadministeredduringtreatmentwithMILBEMAXattherecommendeddose.Inthe

absenceoffurtherstudies,cautionshouldbetakeninthecaseofconcurrentuseof

MILBEMAXandothermacrocycliclactones.Also,nosuchstudieshavebeen

performedwithreproducinganimals.

4.9 Amountstobeadministeredandadministrationroute

Minimumrecommendeddoserate:2mgofmilbemycinoximeand5mgof

praziquantelperkgaregivenonceorally.

Theproductshouldbeadministeredwithoraftersomefood.Doingsoensures

optimumprotectionagainstheartwormdisease.

Dependingonthebodyweightofthecat,thepracticaldosingisasfollows:

Weight Tablets

0.5-1kg: ½tablet

>1 –2kg: 1tablet

MILBEMAXcanbeinsertedintoaprogrammeforpreventionofheartwormdiseaseif

atthesametimetreatmentagainsttapewormsisindicated.MILBEMAXhasa

durationofheartwormpreventionofonemonth.Forregularpreventionofheartworm

diseasetheuseofamonosubstanceispreferred.

4.10Overdose(symptoms,emergencyprocedures,antidotes),ifnecessary

Incaseofoverdose,inadditiontosignsobservedattherecommendeddose(see

4.6),droolingwasobserved.Thissignwillusuallydisappearspontaneouslywithina

MILBEMAXkittenFinalRENEWALSPCJuly2007

4.11Withdrawalperiod(s)

Notapplicable.

5. PHARMACOLOGICALPROPERTIES

Pharmacotherapeuticgroup:Antiparasiticproducts,insecticidesandrepellants-

Endectocides

ATC-vetCode: QP54AB51

5.1. Pharmacodynamicproperties

Milbemycinoximebelongstothegroupofmacrocycliclactones,isolatedfromthe

fermentationofStreptomyceshygroscopicusvar.aureolacrimosus.Itisactiveagainst

mites,againstlarvalandadultstagesofnematodesaswellasagainstlarvaeof

Dirofilariaimmitis.

Theactivityofmilbemycinisrelatedtoitsactiononinvertebrateneurotransmission:

Milbemycinoxime,likeavermectinsandothermilbemycins,increasesnematodeand

insectmembranepermeabilitytochlorideionsviaglutamate-gatedchlorideion

channels(relatedtovertebrateGABA

andglycinereceptors).Thisleadsto

hyperpolarisationoftheneuromuscularmembraneandflaccidparalysisanddeathof

theparasite.

Praziquantelisanacylatedpyrazino-isoquinolinederivative.Praziquantelisactive

againstcestodesandtrematodes.Itmodifiesthepermeabilityforcalcium(influxof

Ca2+)inthemembranesoftheparasiteinducinganimbalanceinthemembrane

structures,leadingtomembranedepolarisationandalmostinstantaneouscontraction

ofthemusculature(tetany),rapidvacuolizationofthesyncytialtegumentand

subsequenttegumentaldisintegration(blebbing),resultingineasierexpulsionfrom

thegastrointestinaltractordeathoftheparasite.

5.2. Pharmacokineticproperties

Inthecat,praziquantelreachespeakplasmaconcentrationswithinanhourafteroral

administration.Thehalflifeofeliminationisaround3hours.

Inthedog,thereisrapidhepaticbiotransformation,prinicipallytomonohydroxylated

derivatives.Theprincipalrouteofeliminationinthedogisrenal.

Afteroraladministrationinthecat,milbemycinoximereachespeakplasma

concentrationswithin2hours.Thehalflifeofeliminationisaround13hours(

9

hours).

Intherat,metabolismappearstobecompletealthoughslow,sinceunchanged

milbemycinoximehasnotbeenfoundinurineorfeces.Mainmetabolitesintherat

aremonohydroxylatedderivatives,attributabletohepaticbiotransformation.In

additiontorelativelyhighliverconcentrations,thereissomeconcentrationinfat,

reflectingitslipophilicity.

MILBEMAXkittenFinalRENEWALSPCJuly2007

6. PHARMACEUTICALPARTICULARS

6.1. Listofexcipients

Core:

Cellulose,microcristalline

Croscarmellosesodium

Povidone

Lactosemonohydrate

Silica,colloidalanhydrous

Magnesiumstearate

Coat:

Hypromellose

Macrogol

Talc

Titaniumdioxide

Ironoxidered

6.2. Incompatibilities

Notapplicable

6.3. Shelflife

Shelf-lifeoftheveterinarymedicinalproductaspackagedforsale:

3years

Shelf-lifeafterfirstopeningoftheimmediatepackaging:

6months

6.4. Specialprecautionsforstorage

Donotstoreabove30°C

Keepblisterintheoutercartontoprotectfromlight

6.5. Natureandcompositionofimmediatepackaging

PVC/PE/PVdC/aluminiumblister

Availablepackagesizes:

Boxwith2tabletsinblister

Boxwith4tabletsinblister

Boxwith10tabletsinblister

Boxwith20tabletsinblister

Boxwith50tabletsinblister

MILBEMAXkittenFinalRENEWALSPCJuly2007

Boxwith100tabletsinblister

Notallpacksizesmaybemarketed

6.6. Specialprecautionsforthedisposalofunusedveterinarymedicinal

productorwastematerialsderivedfromtheuseofsuchproducts

Anyunusedproductorwastematerialshouldbedisposedofinaccordancewithnational

requirements.

Theproductshouldnotcomeintocontactwith(IE'sproposal)watercoursesasthis

maybedangerousforfishandotheraquaticorganisms

7. MARKETINGAUTHORISATIONHOLDER

NovartisAnimalHealthInc.

8. MARKETINGAUTHORISATIONNUMBER(S)

{NationalMANumber(s)}

9. DATEOFFIRSTAUTHORISATION/RENEWALOFTHE AUTHORISATION

{DDMMMYYYY}

10. DATEOFREVISIONOFTHETEXT

{MMMYYYY}

PROHIBITIONOFSALE,SUPPLYAND/ORUSE

4-12-2018

Mylan Expands Its Voluntary Nationwide Recall of Valsartan Tablets, USP, Amlodipine and Valsartan Tablets, USP, and Valsartan and Hydrochlorothiazide Tablets, USP, to all Lots Within Expiry Due to The Detection of Trace Amounts of NDEA (N-Nitrosodiethylam

Mylan Expands Its Voluntary Nationwide Recall of Valsartan Tablets, USP, Amlodipine and Valsartan Tablets, USP, and Valsartan and Hydrochlorothiazide Tablets, USP, to all Lots Within Expiry Due to The Detection of Trace Amounts of NDEA (N-Nitrosodiethylam

– Mylan N.V. (NASDAQ: MYL) today announced that its U.S. based Mylan Pharmaceuticals business is expanding its consumer-level voluntary nationwide recall to include all lots of Valsartan-containing products within expiry. The 104 additional lots include 26 lots of Amlodipine and Valsartan Tablets, USP (including the 5mg/160mg, 10mg/160mg, 5mg/320mg and 10mg/320mg strengths), 51 lots of Valsartan Tablets, USP (including 40 mg, 80 mg, 160 mg and 320 mg strengths), and 27 lots of Valsartan and Hydrochloroth...

FDA - U.S. Food and Drug Administration

27-11-2018

Teva Pharmaceuticals USA Issues Voluntary Nationwide Recall of All Amlodipine/Valsartan Combination Tablets and Amlodipine/Valsartan/Hydrochlorothiazide Combination Tablets That Are Within Expiry

Teva Pharmaceuticals USA Issues Voluntary Nationwide Recall of All Amlodipine/Valsartan Combination Tablets and Amlodipine/Valsartan/Hydrochlorothiazide Combination Tablets That Are Within Expiry

Teva Pharmaceuticals has initiated a voluntary recall in the United States, to the patient level, of all lots of Amlodipine / Valsartan combination tablets and Amlodipine / Valsartan / Hydrochlorothiazide combination tablets (see table below) due to an impurity detected above specification limits in an active pharmaceutical ingredient (API) manufactured by Mylan India. The impurity found in Mylan’s valsartan API is known as N-nitroso-diethylamine (NDEA), which has been classified as a probable human carc...

FDA - U.S. Food and Drug Administration

21-11-2018

Mylan Initiates Voluntary Nationwide Recall of 15 Lots of Valsartan Tablets, USP, Amlodipine and Valsartan Tablets, USP, and Valsartan and Hydrochlorothiazide Tablets, USP, Due to the Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine) Impurity Fou

Mylan Initiates Voluntary Nationwide Recall of 15 Lots of Valsartan Tablets, USP, Amlodipine and Valsartan Tablets, USP, and Valsartan and Hydrochlorothiazide Tablets, USP, Due to the Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine) Impurity Fou

Mylan N.V. (NASDAQ: MYL) today announced that its U.S. based Mylan Pharmaceuticals business is conducting a voluntary nationwide recall to the consumer level of select lots of Valsartan-containing products, including six lots of Amlodipine and Valsartan Tablets, USP (including the 5mg/160mg, 10mg/160mg, and 10mg/320mg strengths), seven lots of Valsartan Tablets, USP (including 40 mg, 80 mg, 160 mg, and 320 mg strengths), and two lots of Valsartan and Hydrochlorothiazide Tablets, USP 320mg/25mg strength. ...

FDA - U.S. Food and Drug Administration

7-9-2018

Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Montelukast Tablets USP, 10mg 30Ct. due to Product/Label Mix-Up

Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Montelukast Tablets USP, 10mg 30Ct. due to Product/Label Mix-Up

Camber Pharmaceuticals, Inc. is voluntarily recalling one single lot of Montelukast Sodium Tablets, USP 10mg, to the consumer level. This recall of one batch of Montelukast Sodium Tablets, USP 10mg, lot# MON17384 Exp. 12/31/2019, was prompted because a complaint of a sealed bottle labeled as Montelukast 10mg 30 ct found to contain 90 tablets of Losartan Potassium Tablets, USP 50mg

FDA - U.S. Food and Drug Administration

1-9-2018

Spodoptera frugiperda partial risk assessment

Spodoptera frugiperda partial risk assessment

Published on: Fri, 31 Aug 2018 00:00:00 +0200 EFSA was asked for a partial risk assessment of Spodoptera frugiperda for the territory of the EU focussing on the main pathways for entry, factors affecting establishment, risk reduction options and pest management. As a polyphagous pest, five commodity pathways were examined in detail. Aggregating across these and other pathways, we estimate that tens of thousands to over a million individual larvae could enter the EU annually on host commodities. Instigat...

Europe - EFSA - European Food Safety Authority Publications

24-5-2018

FDA Approves Semintra, the First FDA-approved Animal Drug for the Control of Systemic Hypertension in Cats

FDA Approves Semintra, the First FDA-approved Animal Drug for the Control of Systemic Hypertension in Cats

The FDA has approved Semintra (telmisartan oral solution), the first FDA-approved animal drug to control systemic hypertension in cats. Semintra is an oral solution administered either directly into the cat’s mouth or on top of a small amount of food.

FDA - U.S. Food and Drug Administration

30-4-2018

Stonewall Kitchen Voluntarily Recalls a Limited Amount of Basil Pesto Aioli due to Mislabeling and Undeclared Presence of the Dairy Allergen, Egg

Stonewall Kitchen Voluntarily Recalls a Limited Amount of Basil Pesto Aioli due to Mislabeling and Undeclared Presence of the Dairy Allergen, Egg

Stonewall Kitchen is voluntarily recalling a limited amount of 10.25oz Basil Pesto Aioli with an Enjoy By date of 28 Sep 2019 which may contain the undeclared allergen egg, as we may have inadvertently placed the label for our Basil Pesto on a small portion of our most recent production run.

FDA - U.S. Food and Drug Administration

22-10-2018

NEXGARD SPECTRA (Merial)

NEXGARD SPECTRA (Merial)

NEXGARD SPECTRA (Active substance: Afoxolaner / milbemycin oxime) - Centralised - 2-Monthly update - Commission Decision (2018)6977 of Mon, 22 Oct 2018 European Medicines Agency (EMA) procedure number: EMEA/V/C/003842/WS1338/0015/G

Europe -DG Health and Food Safety